Stock Analysis on Net
Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Beginner level


Long-term Activity Ratios (Summary)

Johnson & Johnson, long-term (investment) activity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Net fixed asset turnover 4.57 4.75 4.65 4.79 4.72 4.80 4.79 4.89 4.85 4.62 4.50 4.47 4.41 4.46 4.52 4.45 4.44 4.40 4.41
Total asset turnover 0.51 0.53 0.52 0.53 0.52 0.54 0.53 0.52 0.52 0.50 0.49 0.48 0.47 0.50 0.51 0.51 0.51 0.52 0.53
Equity turnover 1.28 1.35 1.38 1.40 1.34 1.38 1.37 1.26 1.28 1.24 1.27 1.01 1.01 1.03 1.02 0.98 0.98 0.97 0.98

Based on: 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Johnson & Johnson’s net fixed asset turnover ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Johnson & Johnson’s total asset turnover ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Johnson & Johnson’s equity turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Net Fixed Asset Turnover

Johnson & Johnson, net fixed asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Sales to customers 18,336  20,691  20,747  20,729  20,562  20,021  20,394  20,348  20,830  20,009  20,195  19,650  18,839  17,766  18,106  17,820  18,482  17,482  17,811  17,102  17,787  17,374 
Property, plant and equipment, net 17,598  17,401  17,658  17,048  17,248  17,000  17,035  16,629  16,632  17,040  17,005  16,628  16,458  16,191  15,912  16,095  15,972  15,964  15,905  15,551  15,583  15,364 
Long-term Activity Ratio
Net fixed asset turnover1 4.57 4.75 4.65 4.79 4.72 4.80 4.79 4.89 4.85 4.62 4.50 4.47 4.41 4.46 4.52 4.45 4.44 4.40 4.41
Benchmarks
Net Fixed Asset Turnover, Competitors2
Abbott Laboratories 3.77 4.06 3.97 4.01 3.95 4.03 4.04 4.08 3.98 3.71 3.60 3.48 3.24 3.07 3.66 3.61 3.53 3.49 3.56
AbbVie Inc. 7.38 11.50 11.23 11.36 11.33 11.42 11.36 10.91 11.10 10.47 10.07 10.11 10.05 10.04 9.85 9.57 9.46 9.16 8.91
Amgen Inc. 4.78 4.68 4.51 4.55 4.58 4.59 4.54 4.51 4.48 4.44 4.37 4.45 4.41 4.41 4.41 4.39 4.41 4.36 4.27
Biogen Inc. 4.35 4.39 4.43 4.54 4.57 4.58 3.74 3.74 3.78 3.78 3.86 3.95 4.14 4.42 4.58 4.78 4.88 4.84 4.92
Bristol-Myers Squibb Co. 6.03 5.07 4.18 5.00 4.92 4.67 4.49 4.33 4.25 4.16 4.15 4.10 4.09 3.98 3.90 3.86 3.83 3.80 3.75
Eli Lilly & Co. 2.88 2.92 2.83 2.90 2.96 3.08 2.75 2.75 2.72 2.61 2.59 2.61 2.56 2.56 2.57 2.53 2.55 2.51 2.48
Gilead Sciences Inc. 4.70 4.90 4.91 5.03 5.16 5.31 5.41 5.76 6.23 7.11 7.79 8.72 9.31 9.80 10.45 11.48 12.29 13.34 14.13
Illumina Inc. 3.77 4.00 3.99 3.95 3.99 3.99 3.10 3.06 3.00 2.99 2.96 3.01 2.97 3.30 3.36 3.74 4.52 5.85 6.48
Merck & Co. Inc. 2.99 3.15 3.11 3.22 3.20 3.19 3.18 3.27 3.27 3.24 3.23 3.27 3.31 3.32 3.31 3.32 3.29 3.19 3.16
Pfizer Inc. 3.49 3.61 3.71 3.87 3.97 4.00 4.01 3.80 3.83 3.77 3.79 3.89 3.91 3.97 3.97 4.01 3.84 3.75 3.55
Regeneron Pharmaceuticals Inc. 2.64 2.71 2.72 2.75 2.70 2.65 2.61 2.52 2.52 2.53 2.49 2.43 2.32 2.19 2.33 2.53 2.62 2.66 2.57
Vertex Pharmaceuticals Inc. 7.42 6.55 5.59 4.93 4.72 4.40 3.75 3.50 3.21 3.02 3.15 3.02 2.88 2.85 2.44 2.42 2.26 1.87 1.48
Zoetis Inc. 3.15 3.21 3.23 3.39 3.48 3.51 3.51 3.68 3.80 3.75 3.70 3.69 3.70 3.62 3.54 3.53 3.62 3.66 3.65

Based on: 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q2 2020 Calculation
Net fixed asset turnover = (Sales to customersQ2 2020 + Sales to customersQ1 2020 + Sales to customersQ4 2019 + Sales to customersQ3 2019) ÷ Property, plant and equipment, net
= (18,336 + 20,691 + 20,747 + 20,729) ÷ 17,598 = 4.57

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Johnson & Johnson’s net fixed asset turnover ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Total Asset Turnover

Johnson & Johnson, total asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Sales to customers 18,336  20,691  20,747  20,729  20,562  20,021  20,394  20,348  20,830  20,009  20,195  19,650  18,839  17,766  18,106  17,820  18,482  17,482  17,811  17,102  17,787  17,374 
Total assets 158,380  155,017  157,728  155,521  155,117  150,027  152,954  155,703  155,365  156,625  157,303  155,658  152,807  144,918  141,208  140,369  139,814  136,231  133,411  133,266  132,036  128,590 
Long-term Activity Ratio
Total asset turnover1 0.51 0.53 0.52 0.53 0.52 0.54 0.53 0.52 0.52 0.50 0.49 0.48 0.47 0.50 0.51 0.51 0.51 0.52 0.53
Benchmarks
Total Asset Turnover, Competitors2
Abbott Laboratories 0.46 0.48 0.47 0.46 0.45 0.45 0.46 0.42 0.43 0.40 0.36 0.35 0.33 0.31 0.40 0.52 0.52 0.51 0.49
AbbVie Inc. 0.24 0.37 0.37 0.55 0.57 0.58 0.55 0.49 0.50 0.43 0.40 0.40 0.40 0.40 0.39 0.38 0.37 0.44 0.43
Amgen Inc. 0.36 0.37 0.37 0.37 0.38 0.35 0.34 0.33 0.33 0.31 0.27 0.27 0.28 0.28 0.28 0.28 0.29 0.28 0.29
Biogen Inc. 0.57 0.55 0.53 0.52 0.54 0.52 0.53 0.52 0.54 0.48 0.52 0.51 0.54 0.54 0.50 0.52 0.52 0.53 0.55
Bristol-Myers Squibb Co. 0.27 0.24 0.20 0.42 0.43 0.67 0.64 0.65 0.66 0.64 0.62 0.61 0.61 0.61 0.58 0.55 0.54 0.53 0.52
Eli Lilly & Co. 0.55 0.56 0.57 0.60 0.60 0.63 0.56 0.54 0.56 0.53 0.51 0.52 0.54 0.57 0.55 0.55 0.56 0.58 0.56
Gilead Sciences Inc. 0.39 0.37 0.36 0.37 0.35 0.35 0.34 0.34 0.35 0.37 0.37 0.42 0.47 0.50 0.53 0.55 0.64 0.68 0.62
Illumina Inc. 0.46 0.49 0.48 0.49 0.49 0.46 0.48 0.48 0.53 0.53 0.52 0.51 0.51 0.53 0.56 0.56 0.58 0.59 0.60
Merck & Co. Inc. 0.52 0.57 0.55 0.55 0.53 0.52 0.51 0.49 0.49 0.47 0.46 0.43 0.43 0.41 0.42 0.41 0.41 0.40 0.39
Pfizer Inc. 0.28 0.30 0.31 0.31 0.34 0.35 0.34 0.32 0.32 0.32 0.31 0.30 0.31 0.31 0.31 0.30 0.31 0.31 0.29
Regeneron Pharmaceuticals Inc. 0.55 0.51 0.53 0.55 0.55 0.54 0.57 0.59 0.62 0.65 0.67 0.63 0.65 0.64 0.70 0.69 0.75 0.75 0.73
Vertex Pharmaceuticals Inc. 0.53 0.54 0.50 0.48 0.49 0.50 0.49 0.61 0.60 0.61 0.70 0.72 0.65 0.69 0.59 0.64 0.61 0.52 0.41
Zoetis Inc. 0.49 0.55 0.54 0.55 0.55 0.54 0.54 0.55 0.65 0.63 0.62 0.55 0.64 0.65 0.64 0.63 0.65 0.65 0.60

Based on: 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q2 2020 Calculation
Total asset turnover = (Sales to customersQ2 2020 + Sales to customersQ1 2020 + Sales to customersQ4 2019 + Sales to customersQ3 2019) ÷ Total assets
= (18,336 + 20,691 + 20,747 + 20,729) ÷ 158,380 = 0.51

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Johnson & Johnson’s total asset turnover ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Equity Turnover

Johnson & Johnson, equity turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 28, 2020 Mar 29, 2020 Dec 29, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 30, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Selected Financial Data (US$ in millions)
Sales to customers 18,336  20,691  20,747  20,729  20,562  20,021  20,394  20,348  20,830  20,009  20,195  19,650  18,839  17,766  18,106  17,820  18,482  17,482  17,811  17,102  17,787  17,374 
Shareholders’ equity 62,978  61,294  59,471  58,210  60,785  58,955  59,752  64,626  62,889  63,255  60,160  73,979  71,922  70,341  70,418  72,769  72,473  72,647  71,150  71,554  71,131  67,878 
Long-term Activity Ratio
Equity turnover1 1.28 1.35 1.38 1.40 1.34 1.38 1.37 1.26 1.28 1.24 1.27 1.01 1.01 1.03 1.02 0.98 0.98 0.97 0.98
Benchmarks
Equity Turnover, Competitors2
Abbott Laboratories 1.03 1.06 1.03 0.99 0.98 0.99 1.00 0.99 0.97 0.91 0.89 0.78 0.75 0.71 1.02 1.00 0.99 0.98 0.96
AbbVie Inc. 2.46 8.33 5.54 4.08 4.44 5.25 5.53 3.90 4.39 5.12 5.79
Amgen Inc. 2.17 2.41 2.30 2.04 2.07 2.07 1.80 1.54 1.48 1.40 0.86 0.68 0.69 0.71 0.73 0.70 0.72 0.74 0.75
Biogen Inc. 1.28 1.15 1.08 1.02 1.09 1.00 1.03 0.96 1.05 0.90 0.97 0.92 1.01 1.00 0.94 0.94 0.99 1.06 1.15
Bristol-Myers Squibb Co. 0.71 0.62 0.51 1.37 1.49 1.53 1.61 1.62 1.75 1.64 1.77 1.39 1.38 1.38 1.20 1.18 1.18 1.18 1.16
Eli Lilly & Co. 5.61 7.50 8.56 6.69 8.35 9.66 2.50 1.86 2.07 1.61 1.97 1.51 1.56 1.54 1.52 1.34 1.41 1.34 1.37
Gilead Sciences Inc. 1.21 1.01 0.98 1.07 0.97 1.00 1.01 0.96 1.05 1.18 1.26 1.09 1.24 1.40 1.59 1.85 2.06 2.42 1.73
Illumina Inc. 0.73 0.77 0.77 0.78 0.79 0.85 0.89 0.93 0.95 0.98 1.00 0.91 0.92 0.95 1.09 1.06 1.13 1.13 1.20
Merck & Co. Inc. 1.71 1.83 1.81 1.71 1.61 1.56 1.58 1.29 1.27 1.21 1.17 1.04 1.01 1.00 0.99 0.91 0.91 0.90 0.88
Pfizer Inc. 0.76 0.78 0.82 0.81 0.90 0.92 0.85 0.75 0.76 0.72 0.74 0.86 0.90 0.90 0.89 0.84 0.83 0.81 0.75
Regeneron Pharmaceuticals Inc. 0.88 0.66 0.71 0.73 0.74 0.73 0.77 0.81 0.86 0.92 0.96 0.91 0.95 1.02 1.09 1.05 1.14 1.18 1.12
Vertex Pharmaceuticals Inc. 0.72 0.75 0.68 0.69 0.68 0.69 0.69 0.97 0.98 1.01 1.23 1.28 1.28 1.35 1.47 1.63 1.59 1.35 1.10
Zoetis Inc. 2.13 2.30 2.31 2.30 2.51 2.55 2.67 2.70 2.84 2.78 3.00 2.58 2.93 3.08 3.29 3.08 3.58 4.14 4.46

Based on: 10-Q (filing date: 2020-07-24), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-18), 10-Q (filing date: 2019-10-28), 10-Q (filing date: 2019-07-29), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-20), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-02), 10-Q (filing date: 2018-05-01), 10-K (filing date: 2018-02-21), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-08), 10-K (filing date: 2017-02-27), 10-Q (filing date: 2016-11-04), 10-Q (filing date: 2016-08-04), 10-Q (filing date: 2016-05-10), 10-K (filing date: 2016-02-24), 10-Q (filing date: 2015-10-30), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).

1 Q2 2020 Calculation
Equity turnover = (Sales to customersQ2 2020 + Sales to customersQ1 2020 + Sales to customersQ4 2019 + Sales to customersQ3 2019) ÷ Shareholders’ equity
= (18,336 + 20,691 + 20,747 + 20,729) ÷ 62,978 = 1.28

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Johnson & Johnson’s equity turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.